CBRE vs MRSN · P/E 43, rev $40.55B vs rev $40.5M
CBRE Group Inc Class A (CBRE) versus Mersana Therapeutics Inc (MRSN) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
Latest reported CBRE revenue for 2025-12-31 was $40.55B. Net income was $1.16B. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. MRSN currently screens at market cap $145.4M.
Not investment advice. Open the CBRE and MRSN stock pages for the full models.
Not investment advice.